62 related articles for article (PubMed ID: 38566211)
1. Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancer.
Gao K; Li X; Ni J; Wu B; Guo J; Zhang R; Wu G
Cancer Lett; 2023 Jul; 566():216247. PubMed ID: 37263338
[TBL] [Abstract][Full Text] [Related]
2. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Graham L; Schweizer MT
Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
[TBL] [Abstract][Full Text] [Related]
3. MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC.
Wang Y; Chen J; Gong L; Wang Y; Siltari A; Lou YR; Murtola TJ; Gao S; Gao Y
J Nanobiotechnology; 2024 Apr; 22(1):145. PubMed ID: 38566211
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
[TBL] [Abstract][Full Text] [Related]
5. Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide.
Hong Z; Xiang Z; Zhang P; Wu Q; Xu C; Wang X; Shi G; Hong Z; Wu D
Clin Transl Med; 2021 Jul; 11(7):e495. PubMed ID: 34323404
[TBL] [Abstract][Full Text] [Related]
6. Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy.
Jiang W; Chen J; Gong C; Wang Y; Gao Y; Yuan Y
J Nanobiotechnology; 2020 Mar; 18(1):50. PubMed ID: 32188463
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
[TBL] [Abstract][Full Text] [Related]
8. Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway.
Chen X; Yang G; Liu M; Quan Z; Wang L; Luo C; Wu X; Zheng Y
Biochem Biophys Res Commun; 2022 Jul; 613():53-60. PubMed ID: 35533600
[TBL] [Abstract][Full Text] [Related]
9. Stromal changes in the aged lung induce an emergence from melanoma dormancy.
Fane ME; Chhabra Y; Alicea GM; Maranto DA; Douglass SM; Webster MR; Rebecca VW; Marino GE; Almeida F; Ecker BL; Zabransky DJ; Hüser L; Beer T; Tang HY; Kossenkov A; Herlyn M; Speicher DW; Xu W; Xu X; Jaffee EM; Aguirre-Ghiso JA; Weeraratna AT
Nature; 2022 Jun; 606(7913):396-405. PubMed ID: 35650435
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic network of EZH2/SFRP1/Wnt in the epithelial-mesenchymal transition of laryngeal carcinoma cells.
Chen W; Wang HT; Ji JF; Wang ZY; Shi T; Wu MH; Yu PJ
Neoplasma; 2022 May; 69(3):680-690. PubMed ID: 35400167
[TBL] [Abstract][Full Text] [Related]
11. Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases.
Su S; Cao J; Meng X; Liu R; Vander Ark A; Woodford E; Zhang R; Stiver I; Zhang X; Madaj ZB; Bowman MJ; Wu Y; Xu HE; Chen B; Yu H; Li X
Cancer Lett; 2022 Jan; 525():170-178. PubMed ID: 34752846
[TBL] [Abstract][Full Text] [Related]
12. Evolving cancer-niche interactions and therapeutic targets during bone metastasis.
Satcher RL; Zhang XH
Nat Rev Cancer; 2022 Feb; 22(2):85-101. PubMed ID: 34611349
[TBL] [Abstract][Full Text] [Related]
13. Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model.
Tyan YS; Lee YP; Chuang HY; Wang WH; Hwang JJ
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33974005
[TBL] [Abstract][Full Text] [Related]
14. The bone microenvironment increases phenotypic plasticity of ER
Bado IL; Zhang W; Hu J; Xu Z; Wang H; Sarkar P; Li L; Wan YW; Liu J; Wu W; Lo HC; Kim IS; Singh S; Janghorban M; Muscarella AM; Goldstein A; Singh P; Jeong HH; Liu C; Schiff R; Huang S; Ellis MJ; Gaber MW; Gugala Z; Liu Z; Zhang XH
Dev Cell; 2021 Apr; 56(8):1100-1117.e9. PubMed ID: 33878299
[TBL] [Abstract][Full Text] [Related]
15. The bone microenvironment invigorates metastatic seeds for further dissemination.
Zhang W; Bado IL; Hu J; Wan YW; Wu L; Wang H; Gao Y; Jeong HH; Xu Z; Hao X; Lege BM; Al-Ouran R; Li L; Li J; Yu L; Singh S; Lo HC; Niu M; Liu J; Jiang W; Li Y; Wong STC; Cheng C; Liu Z; Zhang XH
Cell; 2021 Apr; 184(9):2471-2486.e20. PubMed ID: 33878291
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
